SCHEMBL4773165

SCHEMBL4773165

OC[C@H](Cc1c[nH]cn1)Nc1cc(-c2cccnc2)nc(-c2ccccn2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.39
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 2/20 0.38
RAB9A P51151 2/20 0.38
PKM P14618 1/20 0.38
TSHR P16473 1/20 0.38
DYRK1A Q13627 2/20 0.37
DYRK3 O43781 1/20 0.37
CCNT1 O60563 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK9 P50750 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
DYRK2 Q92630 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
SLC2A1 P11166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4773182 1.00 CYP2A6 (0.39) CYP2A6CYP3A4CYP2C9SMN1; SMN2NPC1
SCHEMBL4775017 0.85 CYP2A6 (0.44) CYP2A6CYP3A4CYP2C9SMN1; SMN2NPC1
SCHEMBL4773513 0.85 CYP2A6 (0.44) CYP2A6CYP3A4CYP2C9SMN1; SMN2NPC1
SCHEMBL4773536 0.85 CYP2A6 (0.44) CYP2A6CYP3A4CYP2C9SMN1; SMN2NPC1
SCHEMBL4774839 0.85 DYRK1A (0.51) CYP2A6CYP3A4CYP2C9SMN1; SMN2NPC1
SCHEMBL4773528 0.82 PTGDR (0.43) CYP2A6CYP3A4CYP2C9SMN1; SMN2NPC1
SCHEMBL4766503 0.81 CDK4 (0.47) DYRK1ADYRK3CDK2PIM1CLK4
SCHEMBL4773620 0.81 CDK4 (0.47) DYRK1ADYRK3CDK2PIM1CLK4
SCHEMBL4766487 0.81 CDK4 (0.47) DYRK1ADYRK3CDK2PIM1CLK4
SCHEMBL4773065 0.79 ADORA1 (0.43) CYP2A6SMN1; SMN2NPC1TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed